7910 Woodmont Avenue,Suite 1210
Bethesda, Maryland 20814, U.S.A. 
info@mlsvfund.com |   +1 301 298 5455

© 2018  by MASA Life Science Ventures, LP

Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal...

January 7, 2020

1/5
Please reload

Featured Posts

Cytox Role of mTOR pathway as a Marker of Risk in Alzheimer's Disease to be Presented at AAIC 2014

July 8, 2014

Manchester, United Kingdom - Cytox, a leading developer of assays for risk assessment and prediction of dementia, announced the timing of a presentation discussing the development of a novel proprietary blood-based assay for the assessment of risk of cognitive decline.

 

The talk, entitled “The evaluation of mTOR pathway dysregulation as a novel blood-based phenotypic risk biomarker for the assessment of Alzheimer’s Disease and dementia” will be given on Thursday 17 July, between 08.30 and 10.00am, during the AAIC Symposia and Featured Research Sessions at the Bella Centre, A/S Convention Center, Copenhagen, by Professor Harald Hampel of Université Pierre et Marie Curie (Sorbonne), Paris, France.

 

More information about the event and Professor Hampel’s presentation can be found on the AAIC Conference website at http://bit.ly/1q9LzXt.

 

The presentation refers to two on-going clinical studies in which blood samples are being collected from patients in Europe and in the United States. One study will examine mTOR dysregulation in well-characterized patients who have been diagnosed with probable Alzheimer ’s Disease, Fronto-temporal Lobe Dementia (FTLD) or Dementia with Lewy bodies (DLB) against cognitively normal control groups.

 

A second study will evaluate the performance of the assay platform in patients with mild cognitive impairment (MCI) assessing the relationship between the assay output (mTOR dysregulation) and the presence or absence of amyloid plaques in the brain, a pathological hallmark of Alzheimer’s Disease, using Positron Emission Tomography (PET) imaging.

 

For more about the mTOR pathway and its potential role in early identification of risk of Dementia and Alzheimer’s disease, follow this link: www.cytoxgroup.com/information-for-editors

 

Source

Tags:

Please reload

NEWS